Home » Stocks » ATRC

AtriCure, Inc. (ATRC)

Stock Price: $65.24 USD 0.46 (0.71%)
Updated Feb 26, 2021 1:34 PM EST - Market open
Market Cap 2.81B
Revenue (ttm) 210.13M
Net Income (ttm) -45.69M
Shares Out 44.01M
EPS (ttm) -1.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $65.24
Previous Close $64.78
Change ($) 0.46
Change (%) 0.71%
Day's Open 65.03
Day's Range 63.93 - 65.86
Day's Volume 245,411
52-Week Range 23.16 - 67.01

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 4 days ago

On Tuesday, February 23, AtriCure (NASDAQ:ATRC) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

Business Wire - 2 weeks ago

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announc...

Business Wire - 3 weeks ago

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that i...

Business Wire - 1 month ago

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary ...

Business Wire - 1 month ago

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that i...

Zacks Investment Research - 2 months ago

AtriCure (ATRC) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Business Wire - 2 months ago

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announc...

Zacks Investment Research - 2 months ago

AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Business Wire - 3 months ago

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announc...

Seeking Alpha - 3 months ago

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

AtriCure (ATRC) delivered earnings and revenue surprises of 67.65% and 13.69%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 3 months ago

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third ...

Zacks Investment Research - 3 months ago

AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 4 months ago

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announc...

Business Wire - 4 months ago

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that i...

Business Wire - 5 months ago

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that t...

Business Wire - 6 months ago

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that A...

Business Wire - 6 months ago

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announc...

Seeking Alpha - 6 months ago

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

AtriCure (ATRC) delivered earnings and revenue surprises of 64.29% and 16.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 6 months ago

Shares of AtriCure (NASDAQ:ATRC) were flatĀ in after-market trading after the company reported Q2 results.

Business Wire - 6 months ago

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second...

Seeking Alpha - 9 months ago

AtriCure, Inc. (ATRC) CEO Michael Carrel on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

AtriCure (ATRC) delivered earnings and revenue surprises of 5.26% and 0.27%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 1 year ago

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

AtriCure has moved higher as of late, but there could definitely be trouble on the horizon for this company.

Seeking Alpha - 1 year ago

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

AtriCure (ATRC) delivered earnings and revenue surprises of -17.86% and 1.90%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

AtriCure's (ATRC) AtriClip devices are currently the most widely implanted left atrial appendage management devices globally.

Seeking Alpha - 1 year ago

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GuruFocus - 1 year ago

President, CEO, & Director of Atricure Inc (NASDAQ:ATRC) Michael H Carrel (insider trades) sold 25,000 shares of ATRC on 07/10/2019 at an average price of $32 a share.

Seeking Alpha - 1 year ago

AtriCure's (ATRC) CEO Mike Carrel on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About ATRC

AtriCure develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energ... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
Aug 5, 2005
CEO
Michael H. Carrel
Stock Exchange
NASDAQ
Ticker Symbol
ATRC
Full Company Profile

Financial Performance

In 2019, AtriCure's revenue was $230.81 million, an increase of 14.47% compared to the previous year's $201.63 million. Losses were -$35.19 million, 66.5% more than in 2018.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for AtriCure stock is "Strong Buy." The 12-month stock price forecast is 70.14, which is an increase of 7.51% from the latest price.

Price Target
$70.14
(7.51% upside)
Analyst Consensus: Strong Buy